RE: Director Dealings14 Jul 2021 10:51
CF restating in the RNS
"Likewise, earlier today Poolbeg Pharma plc filed its Schedule One confirming that it had successfully raised Β£25m in fresh funds on a pre-money valuation of Β£25m, thus when it completes its IPO in the coming week it should be listing with a market cap of c. Β£50m. This is an excellent start to our strategy of spinning off and montizing our non-core assets. We plan and expect to spin off the other three non-core assets between now and year end; namely our 49% stake in Imutex, our 62.6% stake in PrEP Biopharm and Disease in Motion platform business. Thus, we have a very exciting year ahead for Open Orphan."
GLA